Actelion top-40 investor calls J&J buyout "very attractive"

ZURICH, Jan 26 (Reuters) - Johnson & Johnson's $30

billion offer to buy Swiss biotech Actelion including a

plan to spin out a separate research company is "very

attractive", one of Actelion's 40 biggest investors said on

Thursday.

Read more